N-nicotinoyl-gamma-aminobutyric acid sodium salt

Pharmacological properties of the drug N-nicotinoyl-gamma-aminobutyric acid sodium salt

Chemically, it can be considered a combination of the GABA molecule and nicotinic acid. Pharmacologically it combines mainly the properties of these two components. Dilates blood vessels in the brain and also has a tranquilizing, psychostimulating, antiplatelet, antioxidant and nootropic effect. Improves the functional state of the brain by normalizing tissue metabolism and influencing cerebral circulation (increases the volumetric and linear velocity of cerebral blood flow, reduces cerebral vascular resistance, inhibits platelet aggregation, improves microcirculation). When taken as a course, it increases physical and mental performance, reduces headaches, improves memory, and normalizes sleep; helps reduce or eliminate feelings of anxiety, tension, fear; improves the condition of patients with motor and speech disorders. Absorption is fast and complete for any route of administration. Penetrates through the BBB and is retained in body tissues for a long time. Bioavailability is 50–88%. It is excreted mainly by the kidneys unchanged. The half-life is 0.51 hours.

N-nicotinoyl-gamma-aminobutyric acid sodium salt

Trade name of the drug: N-nicotinoyl-gamma-aminobutyric acid sodium salt
International nonproprietary name: Nicotinoyl gamma-aminobutyric acid

Dosage form: Substance-powder.

Active ingredient: Nicotinoyl gamma-aminobutyric acid

Pharmacotherapeutic group:

Nootropics. Correctors for cerebrovascular accidents

Pharmacological properties:

Chemically, it can be considered a combination of the GABA molecule and nicotinic acid. Pharmacologically it combines mainly the properties of these two components. Dilates blood vessels in the brain and also has a tranquilizing, psychostimulating, antiplatelet, antioxidant and nootropic effect. Improves the functional state of the brain by normalizing tissue metabolism and influencing cerebral circulation (increases the volumetric and linear velocity of cerebral blood flow, reduces cerebral vascular resistance, inhibits platelet aggregation, improves microcirculation). When taken as a course, it increases physical and mental performance, reduces headaches, improves memory, and normalizes sleep; helps reduce or eliminate feelings of anxiety, tension, fear; improves the condition of patients with motor and speech disorders.

Absorption is fast and complete by any route of administration. Penetrates through the BBB and is retained in body tissues for a long time. Bioavailability is 50–88%. It is excreted mainly by the kidneys unchanged. The half-life is 0.51 hours.

Indications for use:

cerebrovascular insufficiency, vegetative-vascular dystonia, asthenic syndrome, depressive disorders in old age. Conditions accompanied by anxiety, fear, increased irritability, emotional lability. Asthenic conditions caused by various neuropsychiatric diseases. As part of complex treatment - to relieve acute alcohol intoxication. In chronic alcoholism - to reduce the severity of asthenic, asthenoneurotic, postpsychotic, pre-relapse conditions, as well as alcoholic encephalopathy. Complex therapy includes migraine, traumatic brain injury, and neuroinfection. Open-angle glaucoma (to stabilize visual function). In urological practice (in children over 3 years of age and in adults with urinary disorders) to improve the adaptive function of the bladder (reducing detrusor hypoxia).

Improving the tolerance of physical and mental stress (for persons under intense and extreme conditions of activity; to restore physical performance in athletes, to increase resistance to physical and mental stress).

Contraindications:

Chronic renal failure, individual intolerance to the components of the drug.

Carefully:

Acute cerebrovascular accident.

Pregnancy and lactation:

FDA Recommendations - Category not defined. No studies have been conducted. Contraindicated during pregnancy and lactation.

Interaction with other drugs:

Reduces the period of action of barbiturates, enhances the effect of narcotic analgesics.

Directions for use and dosage:

Inside, regardless of food intake.

For cerebrovascular diseases, a single dose is 0.02–0.05 g 2–3 times a day; daily dose - 0.06-0.15 g. Course of treatment - 1-2 months. Repeated course - after 5-6 months. Depressive states of late age - 0.04–0.2 g/day in 2–3 doses, the optimal interval is 0.06–0.12 g/day for 1.5–3 months.

As an antiasthenic and anxiolytic agent - 0.04-0.08 g/day, if necessary - up to 0.2-0.3 g/day for 1-1.5 months.

For alcoholism during the abstinence period - 0.1–0.15 g/day, in a short course of 6–7 days; for more persistent disorders outside of abstinence - a daily dose of 0.04–0.06 g for 4–5 weeks.

To restore performance and under increased loads - 0.06–0.08 g/day for 1–1.5 months, for athletes at the same dose for 2 weeks of the training period.

IV drip or stream (slow), IM.

Before drip administration, the contents of the ampoule are dissolved in 200 ml of 0.9% sodium chloride solution.

For chronic disorders of cerebral circulation - 0.1–0.2 g intravenously or intramuscularly, 1–2 times a day, in a daily dose of 0.2–0.4 g. Depending on the patient’s condition, it is prescribed in the morning i.v. by drip, in the evening - intramuscularly; or 10 days intravenously, then intramuscularly. The course of treatment is 15–30 days.

For asthenic conditions, depending on the severity of the disease, except for oral administration - intramuscularly, in a daily dose of 0.2–0.4 g (2–4 ml of 10% solution) for 1 month.

For the treatment of alcoholism - 0.6–0.8 g/day. The course of treatment is 1 month.

To relieve acute uncomplicated ethanol intoxication, as part of complex therapy, a saturating dose of 5 mg/kg body weight and a maintenance dose of 1.56 mg/kg/h in a volume of 2.5 liters of infusion solution are administered for 4 hours, morning and evening.

Special instructions:

To prevent migraine attacks, it is prescribed in combination with psychotropic drugs and β-adrenergic receptor blockers.

Side effects:

Increased irritability, agitation, anxiety, dizziness, headache, nausea, allergic reactions (skin rash, itching).

Overdose:

Increased side effects.

Treatment is symptomatic.

Shelf life: 2 years.

Conditions for dispensing from pharmacies: By prescription.

Manufacturer: OJSC “Marbiopharm” (Russia)

Indications for use of the drug N-nicotinoyl-gamma-aminobutyric acid sodium salt

cerebrovascular insufficiency, vegetative-vascular dystonia, asthenic syndrome, depressive disorders in old age. Conditions accompanied by anxiety, fear, increased irritability, emotional lability. Asthenic conditions caused by various neuropsychiatric diseases. As part of complex treatment - to relieve acute alcohol intoxication. In chronic alcoholism - to reduce the severity of asthenic, asthenoneurotic, postpsychotic, pre-relapse conditions, as well as alcoholic encephalopathy. Complex therapy includes migraine, traumatic brain injury, and neuroinfection. Open-angle glaucoma (to stabilize visual function). In urological practice (in children over 3 years of age and in adults with urinary disorders) to improve the adaptive function of the bladder (reducing detrusor hypoxia). Improving the tolerance of physical and mental stress (for persons under intense and extreme conditions of activity; to restore physical performance in athletes, to increase resistance to physical and mental stress).

Use of the drug N-nicotinoyl-gamma-aminobutyric acid sodium salt

Inside, regardless of food intake. For cerebrovascular diseases, a single dose is 0.02–0.05 g 2–3 times a day; daily dose - 0.06-0.15 g. Course of treatment - 1-2 months. Repeated course - after 5-6 months. Depressive states of late age - 0.04–0.2 g/day in 2–3 doses, the optimal interval is 0.06–0.12 g/day for 1.5–3 months. As an antiasthenic and anxiolytic agent - 0.04-0.08 g / day, if necessary - up to 0.2-0.3 g / day for 1-1.5 months. For alcoholism during the abstinence period - 0.1–0.15 g/day, in a short course of 6–7 days; for more persistent disorders outside of abstinence - a daily dose of 0.04–0.06 g for 4–5 weeks. To restore performance and under increased loads - 0.06–0.08 g/day for 1–1.5 months, for athletes at the same dose for 2 weeks of the training period. IV drip or stream (slow), IM. Before drip administration, the contents of the ampoule are dissolved in 200 ml of 0.9% sodium chloride solution. For chronic disorders of cerebral circulation - 0.1–0.2 g intravenously or intramuscularly, 1–2 times a day, in a daily dose of 0.2–0.4 g. Depending on the patient’s condition, it is prescribed in the morning i.v. by drip, in the evening - intramuscularly; or 10 days intravenously, then intramuscularly. The course of treatment is 15–30 days. For asthenic conditions, depending on the severity of the disease, except for oral administration - intramuscularly, in a daily dose of 0.2–0.4 g (2–4 ml of 10% solution) for 1 month. For the treatment of alcoholism - 0.6–0.8 g/day. The course of treatment is 1 month. To relieve acute uncomplicated ethanol intoxication, as part of complex therapy, a saturating dose of 5 mg/kg body weight and a maintenance dose of 1.56 mg/kg/h in a volume of 2.5 liters of infusion solution are administered for 4 hours, morning and evening.

Picamilon tab. 20mg N30

Registration Certificate Holder

PHARMSTANDARD-UFA VITAMIN PLANT (Russia)

Dosage form

Medicine - Picamilon (Picamilon)

Description

Pills

white, flat-cylindrical, chamfered.

1 tab.

N-nicotinoyl-gamma-aminobutyric acid sodium salt 20 mg

Excipients

: potato starch - 18.7 mg, corn starch - 0.6 mg, magnesium hydroxycarbonate (main magnesium carbonate) - 15.53 mg, sucrose - 42.55 mg, calcium stearate - 1 mg, talc - 1.62 mg.

30 pcs. — polymer jars (1) — cardboard packs. 60 pcs. — polymer jars (1) — cardboard packs.

Indications

Cerebrovascular insufficiency, asthenia, depressive disorders in old age.

Conditions accompanied by anxiety, fear, increased irritability, emotional lability. Asthenic conditions caused by various neuropsychiatric diseases.

As part of complex treatment - to relieve acute alcohol intoxication; in chronic alcoholism - to reduce asthenic, asthenoneurotic, postpsychotic, pre-relapse conditions, as well as alcoholic encephalopathy.

Complex therapy includes migraine (prevention), head injury, and neuroinfection.

Improving the tolerance of physical and mental stress (for persons under intense and extreme conditions of activity; to restore the physical performance of athletes, to increase resistance to physical and mental stress).

Open-angle glaucoma (to stabilize visual function).

In urological practice (in children over 3 years of age and in adults with urinary disorders) to improve the adaptive function of the bladder (reducing detrusor hypoxia).

Contraindications for use

Chronic renal failure, pregnancy, lactation, hypersensitivity to nicotinoyl gamma-aminobutyric acid.

pharmachologic effect

Nootropic drug, dilates blood vessels in the brain. It also has a tranquilizing, psychostimulating, antiplatelet and antioxidant effect. Improves the functional state of the brain by normalizing tissue metabolism and influencing cerebral circulation (increases the volumetric and linear velocity of cerebral blood flow, reduces cerebral vascular resistance, suppresses platelet aggregation, improves microcirculation).

When taken as a course, it increases physical and mental performance, reduces headaches, improves memory, and normalizes sleep; helps reduce or eliminate feelings of anxiety, tension, fear; improves the condition of patients with motor and speech disorders.

Drug interactions

Reduces the duration of action of barbiturates.

Enhances the effect of narcotic analgesics.

Dosage regimen

Take orally, regardless of food intake.

For cerebrovascular diseases, a single dose is 20-50 mg 2-3 times a day, a daily dose is 60-150 mg. The course of treatment is 1-2 months. Repeated course - after 5-6 months.

Depressive states of late age: 40-200 mg/day for 2-3 doses, the optimal dose range is 60-120 mg/day for 1.5-3 months. As an antiasthenic and anxiolytic agent - 40-80 mg/day, if necessary - up to 200-300 mg/day, for 1-1.5 months.

For alcoholism during the abstinence period, a dose of 100-150 mg/day is prescribed, for a short course of 6-7 days; for more persistent disorders outside of abstinence - 40-60 mg/day for 4-5 weeks.

To restore performance and under increased loads - 60-80 mg/day for 1-1.5 months, for athletes at the same dose for 2 weeks. training period.

Parenterally administered intravenously, drip or stream (slowly), intramuscularly.

For chronic cerebrovascular accidents - IV or IM, 100-200 mg, 1-2 times a day, daily dose - 20-40 mg. Depending on the patient’s condition, it is used intravenously in the morning and intramuscularly in the evening; or within 10 days intravenously, then intramuscularly. The course of treatment is 15-30 days.

To relieve acute uncomplicated ethanol intoxication, as part of complex therapy, a saturating dose of 5 mg/kg and a maintenance dose of 1.56 mg/kg/h in a volume of 2.5 liters of infusion solution are administered for 4 hours, morning and evening.

For asthenic conditions, depending on the severity of the disease, in addition to oral administration, a daily dose of 20-40 mg is administered intramuscularly for 1 month.

Side effect

From the side of the central nervous system:

irritability, agitation, anxiety, dizziness, headache.
Allergic reactions:
skin rash, itching.

Other:

nausea.

Use during pregnancy and breastfeeding

Restrictions during pregnancy - Contraindicated. Restrictions when breastfeeding - Contraindicated.

Contraindicated for use during pregnancy and lactation (breastfeeding).

Use for renal impairment

Restrictions for impaired renal function - Contraindicated.

Contraindicated in chronic renal failure.